International Pediatric Adrenocortical Tumor Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00700414|
Recruitment Status : Recruiting
First Posted : June 18, 2008
Last Update Posted : November 14, 2017
This study aims to collect demographic and medical information including detailed family history of cancer of children and adolescents with adrenocortical tumors in order to learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients with this rare disease, worldwide.
In addition, investigators at St. Jude Children's Research Hospital (SJCRH) plan to perform molecular studies of tumor cells aimed to clarify the role of the TP53 gene and other genetic pathways in these tumors. They aim to obtain relevant biological material from participants with adrenocortical tumor (ACT), their biological parents, and relatives for determination of the TP53 germline status, molecular studies of the TP53 gene, and other molecular pathways.
|Condition or disease|
Adrenocortical tumors (ACT) are rare cancer types that form in the outer layer of the adrenal gland and are very uncommon in children and teenagers. There is variation in pediatric ACT incidence worldwide. In the United States, only about 25 new cases of ACT per million per year, making this a very rare tumor. However, in southern Brazil, the annual incidence of ACT is 15 times that seen in the United States accounting for 3.4-4.2 per million per year.
Molecular studies have revealed that the majority of children with ACT, particularly those younger than 4 years of age, have constitutional TP53 mutations and/or imprinting defects at chromosome 11p as observed in Beckwith Wiedemann syndrome (BWS) patients. Some mutations, as exemplified by the R337H TP53 germline mutation, in which the function of the mutant protein is relatively preserved, the history of cancer in the carriers and their families is relatively unremarkable. In other cases, the TP53 mutated gene encodes a functionally-impaired protein that predicts for a pervasive history of familial cancer (Li-Fraumeni syndrome). Therefore, these observations have implications for genetic counseling of families with childhood ACT and underscore the importance of genotype-phenotype correlations in familial cancer syndromes.
The creation of a rare tumor registry provides a mechanism to collect information that cannot be gathered in a single institution. The analysis of the registry data would permit an overview of the clinical, epidemiological, current treatment standards, and survival data of these patients and thus create opportunities for research. It also may facilitate the development of treatment consensus among investigators who register their patients and help to design future studies. Moreover, the combined Children's Oncology Group (COG) and IPACTR studies are expected to provide meaningful insight into the biology of ACT, including clinical phenotype/genotype relationships, treatment outcome and long-term follow-up data in subjects with this rare tumor. Finally, it would provide data on the long-term consequences of exposure to tumor-secreted androgens (found in more than 80% of the pediatric cases) on children's growth and development.
|Study Type :||Observational|
|Estimated Enrollment :||9999 participants|
|Official Title:||International Pediatric Adrenocortical Tumor Registry|
|Actual Study Start Date :||October 1, 2001|
|Estimated Primary Completion Date :||December 2040|
|Estimated Study Completion Date :||December 2040|
Any participant who meets eligibility criteria and consents to participate in the trial.
- Collect demographic/medical information, detailed family history of cancer of children/adolescents with adrenocortical tumors, learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients [ Time Frame: Annually from diagnosis until no longer being followed, defined as up to 5 years from the date of last follow-up ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00700414
|Contact: Raul C Ribeiro, MDfirstname.lastname@example.org|
|United States, California|
|Stanford, California, United States, 94305|
|United States, Florida|
|All Children's Hospital/St. Petersburg Hospital||Completed|
|Saint Petersburg, Florida, United States, 33701|
|United States, Ohio|
|The Children's Medical Center||Recruiting|
|Dayton, Ohio, United States, 45404|
|Contact: Mukund Dole, MD|
|Contact: Jenny Dillon, RN, CCRP|
|Principal Investigator: Mukund Dole, MD|
|United States, Tennessee|
|St. Jude Children's Research Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105|
|Contact: Raul C Ribeiro, MD 866-278-5833 email@example.com|
|Principal Investigator: Raul C Ribeiro, MD|
|United States, Texas|
|Cook Children's Medical Center||Completed|
|Fort Worth, Texas, United States, 76104|
|Principal Investigator:||Raul C Ribeiro, MD||St. Jude Children's Research Hospital|